Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00137293 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating GAP-486 in Heart Rhythm
A Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00137293: Clinical Trial Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00137293 is a Phase 2 study that was terminated before completion, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00137293, a Phase 2 study, was terminated before completion, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to learn the effects of a test drug on heart rhythm, and to provide additional data to see if the test drug is well tolerated and safe.
Interventions
- DRUG GAP-486 (ZP-123)
- DRUG 0.9% Sodium Chloride, USP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
Why NCT00137293 stopped before completion
NCT00137293 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which GAP-486 (ZP-123) is the first listed.
NCT00137293 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00137293 about?
NCT00137293 is a clinical study titled "Study Evaluating GAP-486 in Heart Rhythm". The purpose of this study is to learn the effects of a test drug on heart rhythm, and to provide additional data to see if the test drug is well tolerated and safe.
What is the current status of trial NCT00137293?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-11. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00137293?
The interventions under investigation include: GAP-486 (ZP-123) (DRUG), 0.9% Sodium Chloride, USP (DRUG).
Who is sponsoring clinical trial NCT00137293?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00137293's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia